1. Home
  2. UBX vs ACOG Comparison

UBX vs ACOG Comparison

Compare UBX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBX
  • ACOG
  • Stock Information
  • Founded
  • UBX 2009
  • ACOG 2000
  • Country
  • UBX United States
  • ACOG Canada
  • Employees
  • UBX N/A
  • ACOG N/A
  • Industry
  • UBX Biotechnology: Pharmaceutical Preparations
  • ACOG
  • Sector
  • UBX Health Care
  • ACOG
  • Exchange
  • UBX Nasdaq
  • ACOG Nasdaq
  • Market Cap
  • UBX 13.9M
  • ACOG 80.3M
  • IPO Year
  • UBX 2018
  • ACOG N/A
  • Fundamental
  • Price
  • UBX $0.78
  • ACOG $9.33
  • Analyst Decision
  • UBX Strong Buy
  • ACOG Strong Buy
  • Analyst Count
  • UBX 3
  • ACOG 1
  • Target Price
  • UBX $4.67
  • ACOG $20.00
  • AVG Volume (30 Days)
  • UBX 609.1K
  • ACOG 76.9K
  • Earning Date
  • UBX 08-05-2025
  • ACOG 08-14-2025
  • Dividend Yield
  • UBX N/A
  • ACOG N/A
  • EPS Growth
  • UBX N/A
  • ACOG N/A
  • EPS
  • UBX N/A
  • ACOG N/A
  • Revenue
  • UBX N/A
  • ACOG $2,928,654.00
  • Revenue This Year
  • UBX N/A
  • ACOG N/A
  • Revenue Next Year
  • UBX N/A
  • ACOG N/A
  • P/E Ratio
  • UBX N/A
  • ACOG N/A
  • Revenue Growth
  • UBX N/A
  • ACOG N/A
  • 52 Week Low
  • UBX $0.36
  • ACOG $3.75
  • 52 Week High
  • UBX $3.10
  • ACOG $11.40
  • Technical
  • Relative Strength Index (RSI)
  • UBX 48.12
  • ACOG N/A
  • Support Level
  • UBX $0.67
  • ACOG N/A
  • Resistance Level
  • UBX $0.83
  • ACOG N/A
  • Average True Range (ATR)
  • UBX 0.09
  • ACOG 0.00
  • MACD
  • UBX 0.01
  • ACOG 0.00
  • Stochastic Oscillator
  • UBX 24.67
  • ACOG 0.00

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

About ACOG Alpha Cognition Inc. Common Stock

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: